文献速递湿疹皮炎与荨麻疹

诱导性荨麻疹的病理生理与新兴治疗

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-06-16

本文综述了症状性皮肤划痕症、胆碱能性荨麻疹和寒冷性荨麻疹的病理生理机制,指出这些疾病由肥大细胞驱动,涉及IgE依赖和非依赖通路。第二代H1抗组胺药是唯一获批疗法,但许多患者仍无症状缓解;奥马珠单抗对部分难治患者有效但超说明书使用。新兴疗法包括BTK抑制剂、抗KIT单抗、MRGPRX2拮抗剂和IL-4Rα阻断,早期结果 promising,但长期疗效尚不明确。

要点

  • 诱导性荨麻疹由特定刺激触发,机制涉及IgE依赖和非依赖的肥大细胞活化。
  • 第二代H1抗组胺药是唯一获批疗法,但部分患者疗效不足。
  • 奥马珠单抗对难治性患者有效,但属超说明书使用。

核心结论

  • 诱导性荨麻疹涉及异质性机制,包括IgE依赖和非依赖的肥大细胞活化通路。
  • 靶向肥大细胞的新兴疗法早期结果有前景,但能否改变长期病程尚不明确。

研究设计与样本

  • 本文为综述,总结了症状性皮肤划痕症、胆碱能性荨麻疹和寒冷性荨麻疹的病理生理及新兴治疗。

主要发现

  • 诱导性荨麻疹由亚型特异性、明确且可重复的刺激触发,常持续数年并显著损害生活质量。
  • 机制涉及FcεRI、MRGPRX2、CHRM3等受体,以及神经肽、自身抗体和汗液过敏原。
  • 许多患者使用第二代H1抗组胺药后仍有症状,奥马珠单抗对部分难治患者有效但超说明书使用。
  • 新兴疗法包括BTK抑制剂、抗KIT单抗、MRGPRX2拮抗剂和IL-4Rα阻断。

关键数值与推荐

  • 第二代H1抗组胺药是唯一获批疗法。
  • 奥马珠单抗对部分第二代H1抗组胺药难治患者有效,但超说明书使用。

临床怎么用

  • 对诱导性荨麻疹患者应识别触发刺激并评估第二代H1抗组胺药疗效。
  • 难治患者可考虑奥马珠单抗超说明书使用,新兴靶向疗法需进一步验证。

局限性

  • 新兴疗法的早期发现虽有前景,但能否显著改变长期疾病进程尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic inducible urticarias (CIndUs), including symptomatic dermographism (SD), cholinergic urticaria (CholU) and cold urticaria (ColdU), are mast cell (MC)-driven conditions triggered by subtype-specific, definite and reproducible stimuli. Although often considered self-limiting, these diseases can persist for years and significantly impair quality of life. Current evidence suggests that CIndUs involve heterogeneous underlying mechanisms, including both immunoglobulin E (IgE)-dependent and IgE-independent pathways of MC activation. These include activating receptors such as the high-affinity IgE receptor (FcεRI), Mas-related G protein-coupled receptor X2 (MRGPRX2) and muscarinic cholinergic receptor M3 (CHRM3), as well as emerging roles for neuropeptides, autoantibodies and sweat allergens. Many patients remain symptomatic despite treatment with second-generation H1-antihistamines (sgAHs), the only approved therapy. Omalizumab, an anti-IgE monoclonal antibody, is effective in some patients with sgAH-refractory disease but remains off-label for CIndUs. A growing number of clinical trials are investigating therapies that target MCs beyond sgAHs and anti-IgE, including Bruton's tyrosine kinase (BTK) inhibitors, anti-KIT monoclonal antibodies, MRGPRX2 antagonists and blockade of the interleukin-4 receptor alpha chain (IL-4Rα). While early findings are promising, it remains unclear whether these approaches can meaningfully alter the long-term disease course. This review summarizes current understanding of the pathophysiology of SD, CholU and ColdU, and highlights emerging therapies aimed at improving patient outcomes. Improved understanding of CIndU endotypes may enable more personalized, mechanism-based treatment approaches in the future.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Bizjak-Suran M, Fležar M, Pereira MP, et al. Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria. J Eur Acad Dermatol Venereol. 2026. PMID: 42299718. doi:10.1111/jdv.70559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。